# Ultragenyx Pharmaceutical Inc. (RARE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Ultragenyx Pharmaceutical Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/RARE/mda/fy2025/): filed 2026-02-18; accession 0001193125-26-057329 (https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/RARE/mda/fy2024/): filed 2025-02-19; accession 0000950170-25-023312 (https://www.sec.gov/Archives/edgar/data/1515673/000095017025023312/rare-20241231.htm)
- [FY 2023 MD&A](/company/RARE/mda/fy2023/): filed 2024-02-21; accession 0000950170-24-017879 (https://www.sec.gov/Archives/edgar/data/1515673/000095017024017879/rare-20231231.htm)
- [FY 2022 MD&A](/company/RARE/mda/fy2022/): filed 2023-02-17; accession 0000950170-23-003096 (https://www.sec.gov/Archives/edgar/data/1515673/000095017023003096/rare-20221231.htm)
- [FY 2021 MD&A](/company/RARE/mda/fy2021/): filed 2022-02-15; accession 0000950170-22-001284 (https://www.sec.gov/Archives/edgar/data/1515673/000095017022001284/rare-20211231.htm)

Back to /company/RARE/